• about us
• allosteric modulation
• pipeline
• key indications
• business development
• investor center
• press releases
• careers
• contact

ADX10059

ADX10059 is a metabotropic glutamate receptor 5 (mGluR5)  negative allosteric modulator (NAM). The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. 

Thanks in part to Addex, mGluR5 has been shown to be involved in the underlying mechanisms for GERD and migraine. Previous clinical testing by McNeil (now part of Johnson & Johnson) in the 1980’s showed that blocking mGluR5 also is a clinically validated and effective treatment for a chronic form of anxiety, called generalized anxiety disorder.

ADX10059 demostrated efficacy in seperate Phase IIa trials in GERD patients and migraine patients in early 2007; a third Phase IIa showed that ADX10059 was not effective at reducing acute anticipatory dental anxiety (i.e. fear of undergoing dental procedures). However, clinical and preclinical data from Addex and other groups suggest that the product still has potential in chronic forms of anxiety.

Recent research has shown mGluR5 inhibition to be an effective treatment strategy in preclinical models of Parkinson's disease. Addex is pursuing development of another mGluR5 NAM, ADX48621, for treatment of levodopa associated dyskinesia in Parkinson's disease patients and may also move ADX10059 into development for this indication.